Genmab and GSK file for Japanese approval of ofatumumab in CLL
This article was originally published in Scrip
Executive Summary
Genmab and partner GlaxoSmithKline have submitted a Japanese application for the approval of Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL).